<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062463</url>
  </required_header>
  <id_info>
    <org_study_id>BFS-AS-40035</org_study_id>
    <secondary_id>2013-004630-14</secondary_id>
    <nct_id>NCT02062463</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma</brief_title>
  <acronym>ELIOT</acronym>
  <official_title>A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® (160/4.5 and 320/9 mcg) as Compared to SYMBICORT® TURBOHALER® (200/6 and 400/12 mcg) as Treatment for Adult Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to assess whether training participants on proper use of BF SPIROMAX&#xD;
      and Symbicort TURBOHALER will improve their device-handling technique and potentially improve&#xD;
      their treatment outcome, ie, better asthma control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total observed critical errors (technology and handling)</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Adherence according to 6 step standardized device training</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed number of steps taken to achieve device mastery</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction and Preference Questionnaire (PASAPQ) score</measure>
    <time_frame>4 Months</time_frame>
    <description>Fourteen questions which may be scored with answers that range from Very Dissatisfied to Very Satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of different handling errors identified following training</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 6-item ASTHMA CONTROL QUESTIONNAIRE (ACQ)</measure>
    <time_frame>Baseline, week 4, 8, and 12</time_frame>
    <description>7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change in Asthma Treatment</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe asthma exacerbations</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participants with Adverse Events</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>SPIROMAX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.&#xD;
Participants receiving 800 mcg to 1000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 640 mcg and 18 mcg, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TURBOHALER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.&#xD;
Participants receiving 1600 mcg to 2000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 1280 mcg and 36 mcg, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX</intervention_name>
    <description>SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 mcg)</description>
    <arm_group_label>SPIROMAX</arm_group_label>
    <other_name>SPIROMAX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYMBICORT TURBOHALER budesonide and formoterol fumarate</intervention_name>
    <description>SYMBICORT® TURBOHALER® (200/6 and 400/12 mcg)</description>
    <arm_group_label>TURBOHALER</arm_group_label>
    <other_name>SYMBICORT®</other_name>
    <other_name>TURBOHALER®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent signed and dated by the adult patient before conducting any&#xD;
             study related procedures.&#xD;
&#xD;
          -  The patient is a man or woman 18 through 75 years of age as of the screening visit.&#xD;
&#xD;
          -  The patient has a diagnosis of asthma in accordance with Global Initiative for Asthma&#xD;
             (GINA) criteria as evidenced by a United Kingdom (UK) quality outcome framework&#xD;
             approved Read code (UK diagnostic coding system).&#xD;
&#xD;
          -  The patient is receiving step 3 or 4 therapy for asthma as defined by the British&#xD;
             Thoracic Society (BTS) guidelines (daily doses of BDP-equivalent inhaled&#xD;
             corticosteroid (ICS) ≥800 mcg to 2000 mcg as part of fixed or free combinations with&#xD;
             long-acting beta-agonists (LABA).&#xD;
&#xD;
          -  If patient is a female of childbearing potential (postmenarche or less than 2 years&#xD;
             post-menopausal or not surgically sterile) the patient must be willing to commit to&#xD;
             using a medically accepted method of contraception for the duration of study and 30&#xD;
             days after discontinuing study drug.&#xD;
&#xD;
          -  The patient, as judged by the investigator, must be willing and able to understand&#xD;
             risks and benefits of study participation to give informed consent and to comply with&#xD;
             all study requirements as specified in this protocol for the entire duration of their&#xD;
             study participation.&#xD;
&#xD;
          -  The patient is SPIROMAX and TURBOHALER naïve (no use of a TURBOHALER device in the&#xD;
             last 6 months, minimizing carryover from prior device use).&#xD;
&#xD;
          -  If female, the patient must have a negative urine pregnancy test. o other criteria&#xD;
             apply, please contact the investigator for additional information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has any clinically significant uncontrolled medical condition (treated or&#xD;
             untreated) that, in the judgment of the investigator, will cause participation in the&#xD;
             study to be detrimental to the patient.&#xD;
&#xD;
          -  The patient has participated in a Teva sponsored clinical study with BF SPIROMAX in&#xD;
             the last 6 months.&#xD;
&#xD;
          -  The patient is a pregnant, attempting to become pregnant, or breast feeding. (Any&#xD;
             woman becoming pregnant during the study will be withdrawn from the study.)&#xD;
&#xD;
          -  The patient has used a clinical trial investigational drug within 1 month before the&#xD;
             screening visit.&#xD;
&#xD;
          -  The patient has an ongoing asthma exacerbation or has received OCS and/or antibiotics&#xD;
             for a lower respiratory condition (proxy measure for identifying an asthma&#xD;
             exacerbation and/or lower respiratory infection, suggestive of altered inspiratory&#xD;
             capabilities) in the 2 weeks preceding visit&#xD;
&#xD;
          -  The patient is currently receiving any OCS (including long or short courses).&#xD;
&#xD;
          -  The patient has a significant chronic lower respiratory tract disease other than&#xD;
             asthma eg chronic obstructive pulmonary disease (COPD), cystic fibrosis or&#xD;
             interstitial lung disease. Conditions that are not predominant, such as minor degrees&#xD;
             of bronchiectasis, are not a reason for exclusion.&#xD;
&#xD;
          -  The patient has a known allergy or severe sensitivity to the constituents of the study&#xD;
             drugs (SPIROMAX or TURBOHALER) eg, to lactose or to milk protein.&#xD;
&#xD;
               -  other criteria apply, please contact the investigator for additional information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sponsor's Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Branded Pharmaceutical Products R&amp;D, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 34092</name>
      <address>
        <city>Axbridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34081</name>
      <address>
        <city>Babbacombe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34103</name>
      <address>
        <city>Beccles</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34144</name>
      <address>
        <city>Bishops Stortford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34066</name>
      <address>
        <city>Burnhope</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34064</name>
      <address>
        <city>Bury St Edmunds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34107</name>
      <address>
        <city>Bury St Edmunds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34072</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34063</name>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34122</name>
      <address>
        <city>Chipping Norton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34134</name>
      <address>
        <city>Clacton-on-Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34111</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34120</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34126</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34135</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34136</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34143</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34075</name>
      <address>
        <city>Daventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34112</name>
      <address>
        <city>Daventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34083</name>
      <address>
        <city>East Hunsbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34145</name>
      <address>
        <city>East Tillbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34099</name>
      <address>
        <city>Exmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34110</name>
      <address>
        <city>Exmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34102</name>
      <address>
        <city>Goldhay</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34119</name>
      <address>
        <city>Great Yarmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34068</name>
      <address>
        <city>Harrogate</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34079</name>
      <address>
        <city>Harrogate</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34139</name>
      <address>
        <city>Hemel Henpstead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34116</name>
      <address>
        <city>Huntingdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34113</name>
      <address>
        <city>Ipswich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34098</name>
      <address>
        <city>Lancashire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34127</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34128</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34141</name>
      <address>
        <city>Leigh-on-Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34142</name>
      <address>
        <city>Leigh-on-Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34082</name>
      <address>
        <city>Liskeard</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34146</name>
      <address>
        <city>Lister House</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34147</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34080</name>
      <address>
        <city>Loughborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34086</name>
      <address>
        <city>Lowestoft</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34138</name>
      <address>
        <city>Luton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34076</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34109</name>
      <address>
        <city>Newton Aycliffe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34106</name>
      <address>
        <city>Norwich'</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34091</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34095</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34108</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34123</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34085</name>
      <address>
        <city>Oadby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34070</name>
      <address>
        <city>Oldham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34114</name>
      <address>
        <city>Orby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34118</name>
      <address>
        <city>Oxon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34137</name>
      <address>
        <city>Pickering</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34124</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34089</name>
      <address>
        <city>Redditch</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34100</name>
      <address>
        <city>Sheringham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34117</name>
      <address>
        <city>Stalham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34105</name>
      <address>
        <city>Stanley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34065</name>
      <address>
        <city>Stowmarket</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34067</name>
      <address>
        <city>Strensall</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34078</name>
      <address>
        <city>Swindon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34140</name>
      <address>
        <city>Thaxted</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34096</name>
      <address>
        <city>Thornton-Cleveleys</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34077</name>
      <address>
        <city>Trowbridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34088</name>
      <address>
        <city>Trowbridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34071</name>
      <address>
        <city>Waterlooville</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34073</name>
      <address>
        <city>Waterlooville</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34084</name>
      <address>
        <city>Wells-Next-Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34115</name>
      <address>
        <city>Wisbech</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34069</name>
      <address>
        <city>Woodbridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34074</name>
      <address>
        <city>Woodbridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34090</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34121</name>
      <address>
        <city>Wymondham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34101</name>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

